HALIFAX, NOVA SCOTIA--(Marketwired - Oct. 11, 2013) - Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX VENTURE:IMV), a clinical stage vaccine company, has retained B & D Capital Partners ("B & D") to provide strategic investor relations services. B & D will aid the Company in building awareness in the financial community by introducing, maintaining and protecting relationships between the management of the Company and professional investors. Based in Vancouver, British Columbia, the partners of B & D Capital have been instrumental in raising more than $120 million through public and private financings. Don Mosher, a principal in the company, holds shares in Immunovaccine.
Under the terms of the agreement with B & D, the Company will pay B & D a monthly fee of $2,500. The consulting agreement is subject to the approval of the TSX Venture Exchange. The agreement has a term of three months, unless extended in writing, but may be terminated by either party with 30 days written notice.
Immunovaccine Inc. applies its novel technology to the development of vaccines for cancer therapy, infectious diseases and animal health. The Company's DepoVax™ platform is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. Immunovaccine has advanced two DepoVax™-based cancer vaccines into Phase I human clinical trials. The Company is also advancing a broad infectious diseases pipeline including vaccines in such indications as malaria, respiratory syncytial virus (RSV) and anthrax. Connect at www.imvaccine.com.
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.